{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:10:01Z","timestamp":1788862201308,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xjidi.2026.100495","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:51:13Z","timestamp":1780156273000},"page":"100495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3817-8616","authenticated-orcid":false,"given":"Fenna J.","family":"de Bie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5778-4903","authenticated-orcid":false,"given":"Morgann D.","family":"Dettingmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6713-229X","authenticated-orcid":false,"given":"Sanne","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-3647","authenticated-orcid":false,"given":"Willem H.","family":"Zoutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-1514","authenticated-orcid":false,"given":"Sabina Y.","family":"van der Zanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5325-1888","authenticated-orcid":false,"given":"Cornelis P.","family":"Tensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-9023","authenticated-orcid":false,"given":"Ferenc A.","family":"Scheeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-2211","authenticated-orcid":false,"given":"Jacques","family":"Neefjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4613","authenticated-orcid":false,"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100495_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2026.100495_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15482","article-title":"Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: a retrospective study","volume":"35","author":"Di Raimondo","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2026.100495_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13671-018-0214-0","article-title":"What is new in CTCL\u2014Pathogenesis, diagnosis, and treatments","volume":"7","author":"Dulmage","year":"2018","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.xjidi.2026.100495_bib4","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xjidi.2026.100495_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.xjidi.2026.100495_bib6","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and sezary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garcia-Diaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xjidi.2026.100495_bib7","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100495_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00431220","article-title":"A continuous T-cell line from a patient with Sezary syndrome","volume":"279","author":"Kaltoft","year":"1987","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.xjidi.2026.100495_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xjidi.2026.100495_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.leukres.2015.04.006","article-title":"Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed\/refractory mixed-phenotype acute leukemia","volume":"39","author":"Liu","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.xjidi.2026.100495_bib11","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.xjidi.2026.100495_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jid.2019.07.712","article-title":"Overall survival in mycosis fungoides: a systematic review and meta-analysis","volume":"140","author":"Mourad","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100495_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-024-04693-1","article-title":"Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing","volume":"94","author":"Murzyn","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xjidi.2026.100495_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-019-02707-w","article-title":"Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas","volume":"110","author":"Novelli","year":"2019","journal-title":"Inte J Hematol"},{"key":"10.1016\/j.xjidi.2026.100495_bib15","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ncomms2921","article-title":"Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin","volume":"4","author":"Pang","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2026.100495_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-024-02034-7","article-title":"Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients","volume":"23","author":"Qiao","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.xjidi.2026.100495_bib17","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1073\/pnas.1922072117","article-title":"Uncoupling DNA damage from chromatin damage to detoxify doxorubicin","volume":"117","author":"Qiao","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xjidi.2026.100495_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.xjidi.2026.100495_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119527","article-title":"A comprehensive review on time-tested anticancer drug doxorubicin","volume":"278","author":"Sritharan","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.xjidi.2026.100495_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.xjidi.2026.100495_bib21","doi-asserted-by":"crossref","first-page":"13802","DOI":"10.1021\/acs.jmedchem.4c00614","article-title":"Novel N,N-dimethyl-idarubicin analogues are effective cytotoxic agents for ABCB1-overexpressing, doxorubicin-resistant cells","volume":"67","author":"van Gelder","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.xjidi.2026.100495_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.det.2015.05.014","article-title":"Hematopoietic stem cell transplant for mycosis fungoides and sezary syndrome","volume":"33","author":"Virmani","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.xjidi.2026.100495_bib23","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.3390\/cancers14102421","article-title":"Induction of Fatigue by specific anthracycline cancer drugs through disruption of the circadian pacemaker","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.xjidi.2026.100495_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-4-46","article-title":"A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Wei","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.xjidi.2026.100495_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/bjd\/ljad311","article-title":"Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma","volume":"190","author":"Weiner","year":"2024","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.xjidi.2026.100495_bib26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/bjd\/ljaf312","article-title":"European organisation for research and treatment of cancer, united states cutaneous lymphoma consortium and international society for cutaneous lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders","volume":"193","author":"Willemze","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100495_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:14:49Z","timestamp":1788858889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2667026726000482"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100495","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100495"}}